The lack of memory B cells including T cell independent IgM + IgD + memory B cells in chronic graft-versus host disease is associated with susceptibility to infection

Transplant International

Volumn 25, Issue 1, 2012, Pages 87-96

  Hilgendorf, Inken ^a   Mueller Hilke, Brigitte ^a   Kundt, Günther ^a   Holler, Ernst ^b   Hoffmann, Petra ^b   Edinger, Matthias ^b   Freund, Mathias ^a   Wolff, Daniel ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

chronic graft versus host disease; immunoglobulin; infection; lymphocyte; stem cell transplantation

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; IMMUNOLOGIC MEMORY; INFECTION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 83955162245     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01388.x     Document Type: Article

References (47)

1. Socié G,. Chronic GVHD: B cells come of age. Blood 2011; 117: 2086.
2. Bates JS, Engemann AM, Hammond JM,. Clinical utility of rituximab in chronic graft-versus-host disease. Ann Pharmacother 2009; 43: 316.
3. Ratanatharathorn V, Pavletic S, Uberti JP,. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev 2009; 35: 653.
4. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505.
5. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS,. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919.
6. Schultz KR, Paquet J, Bader S, HayGlass KT,. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995; 16: 289.
7. Zhang C, Todorov I, Zhang Z, et al. Donor CD4 + T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107: 2993.
8. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27 + B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 208.
9. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865.
10. Corre E, Carmagnat M, Busson M, et al. Long-term immune deficiency after allogeneic stem cell transplantation: B cell deficiency is associated with late infections. Haematologica 2010; 95: 1025.
11. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973.
12. Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290.
13. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001; 115: 630.
14. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
15. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611.
16. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2011; 17: 1701.
17. Mitchell SA, Kline Leidy N, Mooney KH, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft versus host disease (cGVHD). Bone Marrow Transplant 2010; 45: 762.
18. Cordonnier C, Maury S, Ribaud P, et al. A grading system based on severity of infection to predict mortality in allogeneic stem cell transplant recipients. Transplantation 2006; 82: 86.
19. Ferrara JL, Levine JE, Reddy P, Holler E,. Graft-versus-host disease. Lancet 2009; 373: 1550.
20. Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001; 98: 3505.
21. Storek J, Witherspoon RP, Webb D, Storb R,. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996; 52: 82.
22. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N,. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990; 76: 1647.
23. Storek J, Ferrara J, Ku N., Giorgi JV, Champlin RE, Saxon A,. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387.
24. Abrahamsen IW, Sømme S, Heldal D, Egeland T, Kvale D, Tjønnfjord GE,. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica, 2005; 90: 86.
25. Kuzmina Z, Greinix HAT, Weigl R,. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease associated dysgammaglobulinemia. Blood 2011; 117: 2265.
26. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756.
27. Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60: 3563.
28. Maurer D, Fischer GF, Fae I, et al. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992; 148: 3700.
29. Zinkernagel RM, Hengartner H,. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so called 'immunological memory'. Immunol Rev 2006; 211: 310.
30. D'Orsogna LJ, Wright MP, Krueger RG, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant 2009; 15: 795.
31. Parkkali T, Käyhty H, Ruutu T, Volin L, Eskola J, Ruutu P,. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996; 18: 961.
32. Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K,. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol 1992; 88: 512.
33. Hammarström V, Pauksen K, Azinge J, Oberg G, Ljungman P,. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993; 4: 195.
34. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 939.
35. Picardi M, Selleri C, Rotoli B,. Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. Bone Marrow Transplant 1999; 24: 173.
36. Cuthbert RJ, Iqbal A, Gates A, Toghill PJ, Russell NH,. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol 1995; 48: 257.
37. Kalhs P, Panzer S, Kletter K, et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease. Ann Intern Med 1988; 109: 461.
38. Al-Eid MA, Tutschka PJ, Wagner HN Jr, Santos GW, Tsan MF,. Functional asplenia in patients with chronic graft-versus-host disease: concise communication. J Nucl Med 1983; 24: 1123.
39. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007; 13: 1304.
40. Perreault C, Giasson M, Gyger M, et al. Serum immunoglobulin levels following allogeneic bone marrow transplantation. Blut 1985; 51: 137.
41. Griffith LM, McCoy Jr JP, Bolan CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128: 668.
42. Kelsey SM, Lowdell MW, Newland AC,. IgG subclass levels and immune reconstitution after T cell-depleted allogeneic bone marrow transplantation. Clin Exp Immunol 1990; 80: 409.
43. Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987; 70: 779.
44. Insel RA, Anderson PW,. Response to oligosaccharide-protein conjugate vaccine against Hemophilus influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine. NEJM 1986; 315: 499.
45. Hilgendorf I, Jilg W, Einsele H, et al. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine 2011; 29: 2825.
46. Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol 2009; 29: 130.
47. Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC,. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. J Clin Immunol 2008; 28: S56.